$Burning Rock Biotech (BNR.US)$
NMPA Grants Marketing Approval to the First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer in China
Burning Rock Biotech (NASDAQ: BNR) and Dizal have jointly announced the approval of the first co-developed NGS-based companion diagnostic (CDx) for lung cancer by China's National Medical Products Administration (NMPA). This CDx is designed for EGFR exon 20 insertion mutation (exon20ins) for sunvozertinib, marking a significant milestone in precision...

$Burning Rock Biotech (BNR.US)$
what a stock, no volume but circuit breaker multiple times

$Burning Rock Biotech (BNR.US)$
Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement

$Burning Rock Biotech (BNR.US)$
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
Burning Rock Biotech (NASDAQ: BNR) has announced a collaboration with Bayer to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) in China. This partnership aims to enhance diagnostic methods and enable better treatment choices for cancer patients. The collaboration will focus on developing CDx products for Bayer's precision cancer therapies...

$Burning Rock Biotech (BNR.US)$ hmm early run, new low and news.... see what happens with volume